Eagle’s Eye View: Maintaining Weight Loss With Tirzepatide
In this week’s View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Valvular Heart Disease, Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Acute Heart Failure, Exercise, Mitral Regurgitation, Acute Coronary Syndromes
Keywords: Glucagon-Like Peptide 1, Glucagon-Like Peptide Receptors, Obesity Management, Body Weight Maintenance, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, Apolipoproteins B, Dyslipidemias, Heart Failure, Obesity, Primary Prevention, Oxygen Consumption, Valsartan, Exercise, Mitral Valve Insufficiency, Digitoxin, Digoxin, Atrial Fibrillation, EaglesEyeView
